Abstracts Archive - Page 1341 of 2425 - ACR Meeting Abstracts

Abstract Number: 2032 • 2017 ACR/ARHP Annual Meeting
Evaluation of RA Outcome Measures between Users and Non-Users of the Patient Portal
Sheryl Mascarenhas¹, Shuvro Roy², April Pinto² and Preeta Gupta², ¹Rheumatology, The Ohio State University, Columbus, OH, ²The Ohio State University, Columbus, OH
Background/Purpose: Patient engagement has become a growing focus in healthcare, catalyzed with the passage of the Affordable Care Act in 2010. Stage 2 of…
Abstract Number: 2033 • 2017 ACR/ARHP Annual Meeting
Low Health Literacy Does Not Impact Adherence to Hydroxychloroquine in Patients with Systemic Lupus
Alexandra Perel-Winkler¹, Kayla Neville², Samantha Nguyen¹, Miya Okado¹, James Miceli¹, Jon T. Giles³ and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Low health literacy has been associated with poor health outcomes and increased hospital admissions. Adherence to medication has been shown to significantly impact mortality, morbidity,…
Abstract Number: 2034 • 2017 ACR/ARHP Annual Meeting
New Guidelines on Hydroxychloroquine Dosage – Where Are We?
Shriyanka Jain¹ and John Waterman², ¹Division of Rheumatology, University of Connecticut, School of Medicine, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Hydroxychloroquine (HCQ) is a widely-used medication in many rheumatologic conditions. The most worrisome toxicity is irreversible damage to retinal pigment epithelium which can lead…
Abstract Number: 2035 • 2017 ACR/ARHP Annual Meeting
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Sahil Koppikar¹ and Henry Averns², ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Private Practice, Kingston, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is used widely for the treatment of inflammatory arthritides and systemic lupus erythematosus. Recent publications have shown that HCQ toxicity is not…
Abstract Number: 2036 • 2017 ACR/ARHP Annual Meeting
Rheumatologists’ Compliance with Screening for Viral Hepatitis B and C Prior to Initiation of Methotrexate Treatment Needs Quality Improvement
Farheen Jaffari¹, Andras Perl² and Fatme Allam³, ¹Rheumatology, SUNY Upstate, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: The risk of viral hepatitis reactivation in patients undergoing immunomodulating therapy is being increasingly recognized. The American College of Rheumatology guidelines recommends screening for…
Abstract Number: 2037 • 2017 ACR/ARHP Annual Meeting
HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
Marc W. Nolan^1,2, Morgan M. Brown³ and Elie Gertner^1,2, ¹Section of Rheumatology, Regions Hospital, St. Paul, MN, ²Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ³HealthPartners Institute, St. Paul, MN
Background/Purpose: In 2015, the Canadian Rheumatology Association published their Choosing Wisely recommendations regarding HLA-B27 testing. One of the criteria that triggers testing is inflammatory back…
Abstract Number: 2038 • 2017 ACR/ARHP Annual Meeting
Radiological Changes Measured By MRI and High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Show Correlation with Michigan Hand Outcome Questionnaire (MHQ) in Rheumatoid Arthritis Patients
Ana Cruz¹, Tomohiro Shimizu², Matthew Tanaka³, Kenji Mamoto³, Andrew J Burghardt³, Ursula Heilmeier³, Thomas Link³, Jonathan Graf⁴, John B. Imboden Jr.⁵ and Xiaojuan Li⁶, ¹University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California, San Francisco, SAN FRANCISCO, CA, ³Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁵Medicine, University of California, San Francisco, San Francisco, CA, ⁶Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA
Background/Purpose: Disease progression and therapy response in patients with rheumatoid arthritis (RA) is currently evaluated using clinical and functional assessments that include subjective measurements such…
Abstract Number: 2039 • 2017 ACR/ARHP Annual Meeting
Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference
William Tillett^1,2, Gavin Shaddick³, Bashaar Boyce⁴ and Neil J. McHugh⁵, ¹Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ³Centre for Data Science and Statistics, University of Exeter, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom
Background/Purpose: Participation, including work disability, is an important patient centred outcome and is in the middle ring of the Outcome Measures in Rheumatology (OMERACT) psoriatic…
Abstract Number: 2040 • 2017 ACR/ARHP Annual Meeting
Improving Quality of Care for Rheumatoid Arthritis Patients in an Underserved Area
Qingying Lai¹ and Beverly Johnson², ¹Internal Medicine, Jacobi Medical Center, Bronx, NY, ²Department of Rheumatology, Jacobi Medical Center, Bronx, NY
Background/Purpose: The American College of Rheumatology (ACR) has endorsed a set of quality measurements for patients with rheumatoid arthritis (RA). Our patient population was at…
Abstract Number: 2041 • 2017 ACR/ARHP Annual Meeting
Practice Improvement Utilizing Six Sigma and Health Informatics in an Academic Setting
Puneet Bajaj¹, Shilu Varghese², Allison Sunleaf², Paul Padilla², Shannon Scielzo², Sherene Philip², Justin Haridas², Clarie Wang², Vaishnavi Kannan², Jeffrey Lewis², Deepa Bhat², Jacqueline Mutz², Duwayne Willett², Jason Fish² and David Karp², ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: For projects such as the ACR Rheumatology Informatics System for Effectiveness (RISE) to succeed for quality improvement, practice benchmarking, & research, the data included…
Abstract Number: 2042 • 2017 ACR/ARHP Annual Meeting
Referral Criteria to an Early Arthritis Clinic: Poor Agreement between Referring Physicians and Rheumatologists
Filipa Farinha^1,2, Gisela Eugénio², Mary Marques², Francisco Freitas³, José António P. da Silva^2,4 and Cátia Duarte^2,4, ¹Rheumatology, Centro Hospitalar do Baixo Vouga, E.P.E., Aveiro, Portugal, ²Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Centre for Social Studies, Universidade de Coimbra, Coimbra, Portugal, ⁴Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
Background/Purpose: Prompt identification and referral of patients with suspected inflammatory arthritis to a rheumatology clinic are crucial for early diagnosis and treatment. In the referral…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 2044 • 2017 ACR/ARHP Annual Meeting
Secondary Prevention of Cardiovascular Disease Is Incomplete in a Systemic Lupus Erythematosus Population-Based Cohort
Suzana John¹, Cristina Drenkard², Gaobin Bao² and S. Sam Lim², ¹Rheumatology, Emory University, Atlanta, GA, ²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Cardiovascular disease (CVD) is a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). We know that a combination of traditional cardiovascular…
Abstract Number: 2045 • 2017 ACR/ARHP Annual Meeting
Prophylaxis of Ischemic Disease in Giant Cell Arteritis Patients: An Application of a “Big Data” Tracking Tool in the Electronic Health Record in an University-Based Medical Center
Meera Subash¹, Zunera Tahir² and Arthur Kavanaugh³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Internal Medicine, Div of Rheumatology, Allergy, and Immunology, University of California, San Diego, San Diego, CA, ³Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: The primary objective of this study was to better characterize the prescribed rates of aspirin prophylaxis for ischemic considerations in patients diagnosed with Giant…
Abstract Number: 2046 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Rheumatologist Satisfaction with Practice Scale –“ the Rheumatologist Satisfaction Scale” (RSS)
Khushboo Sheth¹, Antonia Valenzuela², Stanford Shoor³, Philip L. Ritter³ and Kate Lorig⁴, ¹Immunology & Rheumatology, Stanford University, Stanford, CA, ²Immunology and Rheumatology, Stanford University, Palo Alto, CA, ³Immunology & Rheumatology, Stanford University, Palo Alto, CA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Practice improvement research routinely measures patient satisfaction and disease-specific outcomes but seldom considers the satisfaction of physicians who deliver the care. Studies suggest that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].